Journal of Multiple Sclerosis and Neuroimmunology 11(1):14-20, 2020
Update of Autoantibodies in Dermatomyositis
Kyomin Choi, MD, Jeeyoung Oh, MD, PhD
Department of Neurology, Konkuk University Medical Center, Seoul, Korea
Dermatomyositis (DM) is a heterogenous autoimmune muscle disease with systemic
manifestations including skin lesions and lung involvement. Diagnosis and management have
primarily depended on the classification system established by clinical features and muscle
biopsy. Current advances of the identification of myositis-specific autoantibodies (MSAs)
and myositis-associated autoantibodies (MAAs) contribute to exact diagnosis and effective
management. In DM, these autoantibodies showed close correlation with clinical characteristics
of each subtype. We review the MSAs of DM including anti-melanoma differentiation associated
protein 5, anti-Mi-2, anti-transcription intermediary factor 1γ, anti-nuclear matrix protein, and
anti-small ubiquitin-like modifier activating enzyme antibodies for comprehensive management
of patients.
Journal of Multiple Sclerosis and Neuroimmunology 11(1):14-20, 2020
